The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Antibody Drug Conjugate Therapeutics Market Research Report 2024
Synopsis
The global Antibody Drug Conjugate Therapeutics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Antibody Drug Conjugate Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antibody Drug Conjugate Therapeutics.
Report Scope
The Antibody Drug Conjugate Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Antibody Drug Conjugate Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antibody Drug Conjugate Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bayer AG
Pfizer
Hoffman-Le Roche
Seattle Genetics
ImmunoGen
Genentech
Synthon Holding
Sanofi
Genmab
Amgen
Novartis
Eli Lilly
Segment by Type
Mmunomedics Technology
Immunogen Technology
Seattle Genetics Technology
Others
Segment by Application
Lymphoma
Leukemia
Multiple Myeloma
Skin Cancer
Colon Cancer
Glioblastoma
Pancreatic Cancer
Prostate Cancer
Solid Tumor
Breast Cancer
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Antibody Drug Conjugate Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global Antibody Drug Conjugate Therapeutics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Antibody Drug Conjugate Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antibody Drug Conjugate Therapeutics.
Report Scope
The Antibody Drug Conjugate Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Antibody Drug Conjugate Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antibody Drug Conjugate Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bayer AG
Pfizer
Hoffman-Le Roche
Seattle Genetics
ImmunoGen
Genentech
Synthon Holding
Sanofi
Genmab
Amgen
Novartis
Eli Lilly
Segment by Type
Mmunomedics Technology
Immunogen Technology
Seattle Genetics Technology
Others
Segment by Application
Lymphoma
Leukemia
Multiple Myeloma
Skin Cancer
Colon Cancer
Glioblastoma
Pancreatic Cancer
Prostate Cancer
Solid Tumor
Breast Cancer
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Antibody Drug Conjugate Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Antibody Drug Conjugate Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Mmunomedics Technology
1.2.3 Immunogen Technology
1.2.4 Seattle Genetics Technology
1.2.5 Others
1.3 Market by Application
1.3.1 Global Antibody Drug Conjugate Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Lymphoma
1.3.3 Leukemia
1.3.4 Multiple Myeloma
1.3.5 Skin Cancer
1.3.6 Colon Cancer
1.3.7 Glioblastoma
1.3.8 Pancreatic Cancer
1.3.9 Prostate Cancer
1.3.10 Solid Tumor
1.3.11 Breast Cancer
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Antibody Drug Conjugate Therapeutics Market Perspective (2019-2030)
2.2 Antibody Drug Conjugate Therapeutics Growth Trends by Region
2.2.1 Global Antibody Drug Conjugate Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Antibody Drug Conjugate Therapeutics Historic Market Size by Region (2019-2024)
2.2.3 Antibody Drug Conjugate Therapeutics Forecasted Market Size by Region (2025-2030)
2.3 Antibody Drug Conjugate Therapeutics Market Dynamics
2.3.1 Antibody Drug Conjugate Therapeutics Industry Trends
2.3.2 Antibody Drug Conjugate Therapeutics Market Drivers
2.3.3 Antibody Drug Conjugate Therapeutics Market Challenges
2.3.4 Antibody Drug Conjugate Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Antibody Drug Conjugate Therapeutics Players by Revenue
3.1.1 Global Top Antibody Drug Conjugate Therapeutics Players by Revenue (2019-2024)
3.1.2 Global Antibody Drug Conjugate Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Antibody Drug Conjugate Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Antibody Drug Conjugate Therapeutics Revenue
3.4 Global Antibody Drug Conjugate Therapeutics Market Concentration Ratio
3.4.1 Global Antibody Drug Conjugate Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Antibody Drug Conjugate Therapeutics Revenue in 2023
3.5 Antibody Drug Conjugate Therapeutics Key Players Head office and Area Served
3.6 Key Players Antibody Drug Conjugate Therapeutics Product Solution and Service
3.7 Date of Enter into Antibody Drug Conjugate Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Antibody Drug Conjugate Therapeutics Breakdown Data by Type
4.1 Global Antibody Drug Conjugate Therapeutics Historic Market Size by Type (2019-2024)
4.2 Global Antibody Drug Conjugate Therapeutics Forecasted Market Size by Type (2025-2030)
5 Antibody Drug Conjugate Therapeutics Breakdown Data by Application
5.1 Global Antibody Drug Conjugate Therapeutics Historic Market Size by Application (2019-2024)
5.2 Global Antibody Drug Conjugate Therapeutics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Antibody Drug Conjugate Therapeutics Market Size (2019-2030)
6.2 North America Antibody Drug Conjugate Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Antibody Drug Conjugate Therapeutics Market Size by Country (2019-2024)
6.4 North America Antibody Drug Conjugate Therapeutics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Antibody Drug Conjugate Therapeutics Market Size (2019-2030)
7.2 Europe Antibody Drug Conjugate Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Antibody Drug Conjugate Therapeutics Market Size by Country (2019-2024)
7.4 Europe Antibody Drug Conjugate Therapeutics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Antibody Drug Conjugate Therapeutics Market Size (2019-2030)
8.2 Asia-Pacific Antibody Drug Conjugate Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Antibody Drug Conjugate Therapeutics Market Size by Region (2019-2024)
8.4 Asia-Pacific Antibody Drug Conjugate Therapeutics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Antibody Drug Conjugate Therapeutics Market Size (2019-2030)
9.2 Latin America Antibody Drug Conjugate Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Antibody Drug Conjugate Therapeutics Market Size by Country (2019-2024)
9.4 Latin America Antibody Drug Conjugate Therapeutics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Antibody Drug Conjugate Therapeutics Market Size (2019-2030)
10.2 Middle East & Africa Antibody Drug Conjugate Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Antibody Drug Conjugate Therapeutics Market Size by Country (2019-2024)
10.4 Middle East & Africa Antibody Drug Conjugate Therapeutics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Bayer AG
11.1.1 Bayer AG Company Detail
11.1.2 Bayer AG Business Overview
11.1.3 Bayer AG Antibody Drug Conjugate Therapeutics Introduction
11.1.4 Bayer AG Revenue in Antibody Drug Conjugate Therapeutics Business (2019-2024)
11.1.5 Bayer AG Recent Development
11.2 Pfizer
11.2.1 Pfizer Company Detail
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Antibody Drug Conjugate Therapeutics Introduction
11.2.4 Pfizer Revenue in Antibody Drug Conjugate Therapeutics Business (2019-2024)
11.2.5 Pfizer Recent Development
11.3 Hoffman-Le Roche
11.3.1 Hoffman-Le Roche Company Detail
11.3.2 Hoffman-Le Roche Business Overview
11.3.3 Hoffman-Le Roche Antibody Drug Conjugate Therapeutics Introduction
11.3.4 Hoffman-Le Roche Revenue in Antibody Drug Conjugate Therapeutics Business (2019-2024)
11.3.5 Hoffman-Le Roche Recent Development
11.4 Seattle Genetics
11.4.1 Seattle Genetics Company Detail
11.4.2 Seattle Genetics Business Overview
11.4.3 Seattle Genetics Antibody Drug Conjugate Therapeutics Introduction
11.4.4 Seattle Genetics Revenue in Antibody Drug Conjugate Therapeutics Business (2019-2024)
11.4.5 Seattle Genetics Recent Development
11.5 ImmunoGen
11.5.1 ImmunoGen Company Detail
11.5.2 ImmunoGen Business Overview
11.5.3 ImmunoGen Antibody Drug Conjugate Therapeutics Introduction
11.5.4 ImmunoGen Revenue in Antibody Drug Conjugate Therapeutics Business (2019-2024)
11.5.5 ImmunoGen Recent Development
11.6 Genentech
11.6.1 Genentech Company Detail
11.6.2 Genentech Business Overview
11.6.3 Genentech Antibody Drug Conjugate Therapeutics Introduction
11.6.4 Genentech Revenue in Antibody Drug Conjugate Therapeutics Business (2019-2024)
11.6.5 Genentech Recent Development
11.7 Synthon Holding
11.7.1 Synthon Holding Company Detail
11.7.2 Synthon Holding Business Overview
11.7.3 Synthon Holding Antibody Drug Conjugate Therapeutics Introduction
11.7.4 Synthon Holding Revenue in Antibody Drug Conjugate Therapeutics Business (2019-2024)
11.7.5 Synthon Holding Recent Development
11.8 Sanofi
11.8.1 Sanofi Company Detail
11.8.2 Sanofi Business Overview
11.8.3 Sanofi Antibody Drug Conjugate Therapeutics Introduction
11.8.4 Sanofi Revenue in Antibody Drug Conjugate Therapeutics Business (2019-2024)
11.8.5 Sanofi Recent Development
11.9 Genmab
11.9.1 Genmab Company Detail
11.9.2 Genmab Business Overview
11.9.3 Genmab Antibody Drug Conjugate Therapeutics Introduction
11.9.4 Genmab Revenue in Antibody Drug Conjugate Therapeutics Business (2019-2024)
11.9.5 Genmab Recent Development
11.10 Amgen
11.10.1 Amgen Company Detail
11.10.2 Amgen Business Overview
11.10.3 Amgen Antibody Drug Conjugate Therapeutics Introduction
11.10.4 Amgen Revenue in Antibody Drug Conjugate Therapeutics Business (2019-2024)
11.10.5 Amgen Recent Development
11.11 Novartis
11.11.1 Novartis Company Detail
11.11.2 Novartis Business Overview
11.11.3 Novartis Antibody Drug Conjugate Therapeutics Introduction
11.11.4 Novartis Revenue in Antibody Drug Conjugate Therapeutics Business (2019-2024)
11.11.5 Novartis Recent Development
11.12 Eli Lilly
11.12.1 Eli Lilly Company Detail
11.12.2 Eli Lilly Business Overview
11.12.3 Eli Lilly Antibody Drug Conjugate Therapeutics Introduction
11.12.4 Eli Lilly Revenue in Antibody Drug Conjugate Therapeutics Business (2019-2024)
11.12.5 Eli Lilly Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Antibody Drug Conjugate Therapeutics Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Mmunomedics Technology
Table 3. Key Players of Immunogen Technology
Table 4. Key Players of Seattle Genetics Technology
Table 5. Key Players of Others
Table 6. Global Antibody Drug Conjugate Therapeutics Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Antibody Drug Conjugate Therapeutics Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 8. Global Antibody Drug Conjugate Therapeutics Market Size by Region (2019-2024) & (US$ Million)
Table 9. Global Antibody Drug Conjugate Therapeutics Market Share by Region (2019-2024)
Table 10. Global Antibody Drug Conjugate Therapeutics Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 11. Global Antibody Drug Conjugate Therapeutics Market Share by Region (2025-2030)
Table 12. Antibody Drug Conjugate Therapeutics Market Trends
Table 13. Antibody Drug Conjugate Therapeutics Market Drivers
Table 14. Antibody Drug Conjugate Therapeutics Market Challenges
Table 15. Antibody Drug Conjugate Therapeutics Market Restraints
Table 16. Global Antibody Drug Conjugate Therapeutics Revenue by Players (2019-2024) & (US$ Million)
Table 17. Global Antibody Drug Conjugate Therapeutics Market Share by Players (2019-2024)
Table 18. Global Top Antibody Drug Conjugate Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antibody Drug Conjugate Therapeutics as of 2023)
Table 19. Ranking of Global Top Antibody Drug Conjugate Therapeutics Companies by Revenue (US$ Million) in 2023
Table 20. Global 5 Largest Players Market Share by Antibody Drug Conjugate Therapeutics Revenue (CR5 and HHI) & (2019-2024)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Antibody Drug Conjugate Therapeutics Product Solution and Service
Table 23. Date of Enter into Antibody Drug Conjugate Therapeutics Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Antibody Drug Conjugate Therapeutics Market Size by Type (2019-2024) & (US$ Million)
Table 26. Global Antibody Drug Conjugate Therapeutics Revenue Market Share by Type (2019-2024)
Table 27. Global Antibody Drug Conjugate Therapeutics Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 28. Global Antibody Drug Conjugate Therapeutics Revenue Market Share by Type (2025-2030)
Table 29. Global Antibody Drug Conjugate Therapeutics Market Size by Application (2019-2024) & (US$ Million)
Table 30. Global Antibody Drug Conjugate Therapeutics Revenue Market Share by Application (2019-2024)
Table 31. Global Antibody Drug Conjugate Therapeutics Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 32. Global Antibody Drug Conjugate Therapeutics Revenue Market Share by Application (2025-2030)
Table 33. North America Antibody Drug Conjugate Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 34. North America Antibody Drug Conjugate Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 35. North America Antibody Drug Conjugate Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 36. Europe Antibody Drug Conjugate Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 37. Europe Antibody Drug Conjugate Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 38. Europe Antibody Drug Conjugate Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 39. Asia-Pacific Antibody Drug Conjugate Therapeutics Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 40. Asia-Pacific Antibody Drug Conjugate Therapeutics Market Size by Region (2019-2024) & (US$ Million)
Table 41. Asia-Pacific Antibody Drug Conjugate Therapeutics Market Size by Region (2025-2030) & (US$ Million)
Table 42. Latin America Antibody Drug Conjugate Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 43. Latin America Antibody Drug Conjugate Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 44. Latin America Antibody Drug Conjugate Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Antibody Drug Conjugate Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 46. Middle East & Africa Antibody Drug Conjugate Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 47. Middle East & Africa Antibody Drug Conjugate Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 48. Bayer AG Company Detail
Table 49. Bayer AG Business Overview
Table 50. Bayer AG Antibody Drug Conjugate Therapeutics Product
Table 51. Bayer AG Revenue in Antibody Drug Conjugate Therapeutics Business (2019-2024) & (US$ Million)
Table 52. Bayer AG Recent Development
Table 53. Pfizer Company Detail
Table 54. Pfizer Business Overview
Table 55. Pfizer Antibody Drug Conjugate Therapeutics Product
Table 56. Pfizer Revenue in Antibody Drug Conjugate Therapeutics Business (2019-2024) & (US$ Million)
Table 57. Pfizer Recent Development
Table 58. Hoffman-Le Roche Company Detail
Table 59. Hoffman-Le Roche Business Overview
Table 60. Hoffman-Le Roche Antibody Drug Conjugate Therapeutics Product
Table 61. Hoffman-Le Roche Revenue in Antibody Drug Conjugate Therapeutics Business (2019-2024) & (US$ Million)
Table 62. Hoffman-Le Roche Recent Development
Table 63. Seattle Genetics Company Detail
Table 64. Seattle Genetics Business Overview
Table 65. Seattle Genetics Antibody Drug Conjugate Therapeutics Product
Table 66. Seattle Genetics Revenue in Antibody Drug Conjugate Therapeutics Business (2019-2024) & (US$ Million)
Table 67. Seattle Genetics Recent Development
Table 68. ImmunoGen Company Detail
Table 69. ImmunoGen Business Overview
Table 70. ImmunoGen Antibody Drug Conjugate Therapeutics Product
Table 71. ImmunoGen Revenue in Antibody Drug Conjugate Therapeutics Business (2019-2024) & (US$ Million)
Table 72. ImmunoGen Recent Development
Table 73. Genentech Company Detail
Table 74. Genentech Business Overview
Table 75. Genentech Antibody Drug Conjugate Therapeutics Product
Table 76. Genentech Revenue in Antibody Drug Conjugate Therapeutics Business (2019-2024) & (US$ Million)
Table 77. Genentech Recent Development
Table 78. Synthon Holding Company Detail
Table 79. Synthon Holding Business Overview
Table 80. Synthon Holding Antibody Drug Conjugate Therapeutics Product
Table 81. Synthon Holding Revenue in Antibody Drug Conjugate Therapeutics Business (2019-2024) & (US$ Million)
Table 82. Synthon Holding Recent Development
Table 83. Sanofi Company Detail
Table 84. Sanofi Business Overview
Table 85. Sanofi Antibody Drug Conjugate Therapeutics Product
Table 86. Sanofi Revenue in Antibody Drug Conjugate Therapeutics Business (2019-2024) & (US$ Million)
Table 87. Sanofi Recent Development
Table 88. Genmab Company Detail
Table 89. Genmab Business Overview
Table 90. Genmab Antibody Drug Conjugate Therapeutics Product
Table 91. Genmab Revenue in Antibody Drug Conjugate Therapeutics Business (2019-2024) & (US$ Million)
Table 92. Genmab Recent Development
Table 93. Amgen Company Detail
Table 94. Amgen Business Overview
Table 95. Amgen Antibody Drug Conjugate Therapeutics Product
Table 96. Amgen Revenue in Antibody Drug Conjugate Therapeutics Business (2019-2024) & (US$ Million)
Table 97. Amgen Recent Development
Table 98. Novartis Company Detail
Table 99. Novartis Business Overview
Table 100. Novartis Antibody Drug Conjugate Therapeutics Product
Table 101. Novartis Revenue in Antibody Drug Conjugate Therapeutics Business (2019-2024) & (US$ Million)
Table 102. Novartis Recent Development
Table 103. Eli Lilly Company Detail
Table 104. Eli Lilly Business Overview
Table 105. Eli Lilly Antibody Drug Conjugate Therapeutics Product
Table 106. Eli Lilly Revenue in Antibody Drug Conjugate Therapeutics Business (2019-2024) & (US$ Million)
Table 107. Eli Lilly Recent Development
Table 108. Research Programs/Design for This Report
Table 109. Key Data Information from Secondary Sources
Table 110. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Antibody Drug Conjugate Therapeutics Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Antibody Drug Conjugate Therapeutics Market Share by Type: 2023 VS 2030
Figure 3. Mmunomedics Technology Features
Figure 4. Immunogen Technology Features
Figure 5. Seattle Genetics Technology Features
Figure 6. Others Features
Figure 7. Global Antibody Drug Conjugate Therapeutics Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global Antibody Drug Conjugate Therapeutics Market Share by Application: 2023 VS 2030
Figure 9. Lymphoma Case Studies
Figure 10. Leukemia Case Studies
Figure 11. Multiple Myeloma Case Studies
Figure 12. Skin Cancer Case Studies
Figure 13. Colon Cancer Case Studies
Figure 14. Glioblastoma Case Studies
Figure 15. Pancreatic Cancer Case Studies
Figure 16. Prostate Cancer Case Studies
Figure 17. Solid Tumor Case Studies
Figure 18. Breast Cancer Case Studies
Figure 19. Antibody Drug Conjugate Therapeutics Report Years Considered
Figure 20. Global Antibody Drug Conjugate Therapeutics Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 21. Global Antibody Drug Conjugate Therapeutics Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 22. Global Antibody Drug Conjugate Therapeutics Market Share by Region: 2023 VS 2030
Figure 23. Global Antibody Drug Conjugate Therapeutics Market Share by Players in 2023
Figure 24. Global Top Antibody Drug Conjugate Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antibody Drug Conjugate Therapeutics as of 2023)
Figure 25. The Top 10 and 5 Players Market Share by Antibody Drug Conjugate Therapeutics Revenue in 2023
Figure 26. North America Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. North America Antibody Drug Conjugate Therapeutics Market Share by Country (2019-2030)
Figure 28. United States Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Canada Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Europe Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Europe Antibody Drug Conjugate Therapeutics Market Share by Country (2019-2030)
Figure 32. Germany Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. France Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. U.K. Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Italy Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Russia Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Nordic Countries Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Asia-Pacific Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Asia-Pacific Antibody Drug Conjugate Therapeutics Market Share by Region (2019-2030)
Figure 40. China Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Japan Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. South Korea Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Southeast Asia Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. India Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Australia Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Latin America Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Latin America Antibody Drug Conjugate Therapeutics Market Share by Country (2019-2030)
Figure 48. Mexico Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 49. Brazil Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 50. Middle East & Africa Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 51. Middle East & Africa Antibody Drug Conjugate Therapeutics Market Share by Country (2019-2030)
Figure 52. Turkey Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 53. Saudi Arabia Antibody Drug Conjugate Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 54. Bayer AG Revenue Growth Rate in Antibody Drug Conjugate Therapeutics Business (2019-2024)
Figure 55. Pfizer Revenue Growth Rate in Antibody Drug Conjugate Therapeutics Business (2019-2024)
Figure 56. Hoffman-Le Roche Revenue Growth Rate in Antibody Drug Conjugate Therapeutics Business (2019-2024)
Figure 57. Seattle Genetics Revenue Growth Rate in Antibody Drug Conjugate Therapeutics Business (2019-2024)
Figure 58. ImmunoGen Revenue Growth Rate in Antibody Drug Conjugate Therapeutics Business (2019-2024)
Figure 59. Genentech Revenue Growth Rate in Antibody Drug Conjugate Therapeutics Business (2019-2024)
Figure 60. Synthon Holding Revenue Growth Rate in Antibody Drug Conjugate Therapeutics Business (2019-2024)
Figure 61. Sanofi Revenue Growth Rate in Antibody Drug Conjugate Therapeutics Business (2019-2024)
Figure 62. Genmab Revenue Growth Rate in Antibody Drug Conjugate Therapeutics Business (2019-2024)
Figure 63. Amgen Revenue Growth Rate in Antibody Drug Conjugate Therapeutics Business (2019-2024)
Figure 64. Novartis Revenue Growth Rate in Antibody Drug Conjugate Therapeutics Business (2019-2024)
Figure 65. Eli Lilly Revenue Growth Rate in Antibody Drug Conjugate Therapeutics Business (2019-2024)
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
